Reverse Phase Protein Arrays and Drug Discovery

Kenneth G. Macleod; Bryan Serrels; Neil O. Carragher

doi:10.1007/978-1-4939-7201-2_10

Reverse Phase Protein Arrays and Drug Discovery

Kenneth G. Macleod, Bryan Serrels, Neil O. Carragher

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract / Description of output

Reverse Phase Protein Arrays (RPPA) represent a sensitive antibody-based proteomic approach, which enables simultaneous quantification of the abundance of multiple proteins and posttranslational modifications across multiple samples. Here, we provide protocols for RPPA performed on two distinct protein-binding substrates associated with two most commonly used RPPA platform technologies. We compare and contrast the respective advantages and limitations of each platform within the context of drug discovery applications.

Original language	English
Title of host publication	Proteomics for Drug Discovery
Pages	153-169
DOIs	https://doi.org/10.1007/978-1-4939-7201-2_10
Publication status	Published - 15 Aug 2017

Publication series

Name	Proteomics for Drug Discovery
Volume	1647
ISSN (Print)	1064-3745
ISSN (Electronic)	1940-6029

Access to Document

10.1007/978-1-4939-7201-2_10

http://link.springer.com/10.1007/978-1-4939-7201-2_10

Cite this

@inbook{8f779b8397b24914b8db318787c8a1ff,

title = "Reverse Phase Protein Arrays and Drug Discovery",

abstract = "Reverse Phase Protein Arrays (RPPA) represent a sensitive antibody-based proteomic approach, which enables simultaneous quantification of the abundance of multiple proteins and posttranslational modifications across multiple samples. Here, we provide protocols for RPPA performed on two distinct protein-binding substrates associated with two most commonly used RPPA platform technologies. We compare and contrast the respective advantages and limitations of each platform within the context of drug discovery applications.",

author = "Macleod, {Kenneth G.} and Bryan Serrels and Carragher, {Neil O.}",

year = "2017",

month = aug,

day = "15",

doi = "10.1007/978-1-4939-7201-2_10",

language = "English",

series = "Proteomics for Drug Discovery",

pages = "153--169",

booktitle = "Proteomics for Drug Discovery",

}

TY - CHAP

T1 - Reverse Phase Protein Arrays and Drug Discovery

AU - Macleod, Kenneth G.

AU - Serrels, Bryan

AU - Carragher, Neil O.

PY - 2017/8/15

Y1 - 2017/8/15

N2 - Reverse Phase Protein Arrays (RPPA) represent a sensitive antibody-based proteomic approach, which enables simultaneous quantification of the abundance of multiple proteins and posttranslational modifications across multiple samples. Here, we provide protocols for RPPA performed on two distinct protein-binding substrates associated with two most commonly used RPPA platform technologies. We compare and contrast the respective advantages and limitations of each platform within the context of drug discovery applications.

AB - Reverse Phase Protein Arrays (RPPA) represent a sensitive antibody-based proteomic approach, which enables simultaneous quantification of the abundance of multiple proteins and posttranslational modifications across multiple samples. Here, we provide protocols for RPPA performed on two distinct protein-binding substrates associated with two most commonly used RPPA platform technologies. We compare and contrast the respective advantages and limitations of each platform within the context of drug discovery applications.

U2 - 10.1007/978-1-4939-7201-2_10

DO - 10.1007/978-1-4939-7201-2_10

M3 - Chapter

T3 - Proteomics for Drug Discovery

SP - 153

EP - 169

BT - Proteomics for Drug Discovery

ER -

Reverse Phase Protein Arrays and Drug Discovery

Abstract / Description of output

Publication series

Access to Document

Fingerprint

Cite this